Rabies immunoglobulin

From WikiProjectMed
Jump to navigation Jump to search
Rabies immunoglobulin
Names
Trade namesImogam Rabies-HT, Kedrab, HyperRab, others
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Defined daily dosenot established[1]
External links
AHFS/Drugs.comMonograph
Legal
Legal status

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus.[2] It is used to prevent rabies following exposure.[2] It is given after the wound is cleaned with soap and water or povidone-iodine and is followed by a course of rabies vaccine.[2] It is given by injection into the site of the wound and into a muscle.[2] It is not needed in people who have been previously vaccinated against rabies.[3]

Common side effects include pain at the site of injection, fever, and headache.[2] Severe allergic reactions such as anaphylaxis may rarely occur.[4] Use during pregnancy is not known to harm the baby.[2] It works by binding to the rabies virus before it can enter nerve tissue.[2] After the virus has entered the central nervous system, rabies immunoglobulin is no longer useful.[2]

The use of rabies immunoglobulin in the form of blood serum dates from 1891.[5] Use became common within medicine in the 1950s.[6] It is on the World Health Organization's List of Essential Medicines.[7] Rabies immunoglobulin is expensive and hard to come by in the developing world.[8] In the United States it is estimated to be more than US$1,000 per dose.[9] It is made from the blood plasma of people or horses who have high levels of the antibody in their blood.[2][9] The horse version is less expensive but has a higher rate of side effects.[9][6]

Medical uses

Dosage

The defined daily dose is not established.[1]

Availability

There are three versions of rabies immunoglobulin licensed and available in the US.[10] Imogam Rabies-HT is produced by Sanofi Pasteur.[11] Kedrab is produced by Kedrion Biopharma.[12][13] HyperRab is produced by Grifols.[14]

Imogam Rabies-HT and Kedrab have a nominal potency of 150 IU/mL while HyperRab has a nominal potency of 300 IU/mL and requires smaller dosing. All three versions are used for post-exposure[15] and indicate local infusion at the wound site with additional amount intramuscularly at a site distant from vaccine administration.[medical citation needed]

References

  1. 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 15 September 2020.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 "Rabies Immune Globulin". The American Society of Health-System Pharmacists. Archived from the original on 24 September 2017. Retrieved 8 January 2017.
  3. World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 398. hdl:10665/44053. ISBN 9789241547659.
  4. British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 869. ISBN 9780857111562.
  5. Plotkin, [edited by] Stanley A.; Orenstein, Walter A.; Offit, Paul A. (2013). Vaccines (6th ed.). [Edinburgh]: Elsevier/Saunders. p. 659. ISBN 978-1455700905. Archived from the original on 2017-01-09.CS1 maint: extra text: authors list (link)
  6. 6.0 6.1 Jong, Elaine C.; Zuckerman, Jane N. (2004). Travelers' Vaccines. PMPH-USA. p. 205. ISBN 9781550092257. Archived from the original on 2017-01-09.
  7. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. Tintinalli, Judith E. (2010). Emergency Medicine: A Comprehensive Study Guide (Emergency Medicine (Tintinalli)) (7 ed.). New York: McGraw-Hill Companies. p. 1054. ISBN 978-0-07-148480-0.
  9. 9.0 9.1 9.2 Research Advances in Rabies. Academic Press. 2011. p. 351. ISBN 9780123870414. Archived from the original on 2017-01-09.
  10. "Vaccine and Immune Globulin Availability". Centers for Disease Control and Prevention (CDC). 2020-02-26. Retrieved 2020-03-24.
  11. "Imogam Rabies-HT - human rabies virus immune globulin injection, solution". DailyMed. Retrieved 2020-03-24.
  12. "Kedrab". U.S. Food and Drug Administration (FDA). 21 March 2018. Retrieved 7 June 2020.
  13. "Kedrab- human rabies virus immune globulin injection, solution". DailyMed. Retrieved 2020-03-24.
  14. "HyperRab (rabies immune globulin- human injection, solution". DailyMed. Retrieved 2020-03-24.
  15. "WHO Guide for Rabies Pre and Post Exposure Prophylaxis in Humans" (PDF). World Health Organization (WHO). 2014.

External links

Identifiers: